论文部分内容阅读
[《美国医学协会杂志》1989年6月] 美国食品药品管理局以及生产哌氟酰胺(flecainide)和哌茴苯胺(encainide)的药厂已经通知内科医师,这两种药仅应用于有威胁生命危险的心律失常病人,例如持续性的室性心动过速。根据控制心律失常试验(Cardiac Arrhythmia Suppression Trial,CAST)的结果,认为这两种药不应用于不太严重的室性心律失常,即使病人是表现有症状的。CAST 研究工作的设计是对最近有过一次心脏病发作的病人发生异常的室性早搏,试验药物能否消除他们的心律失常,从而降低病死率。因为在心脏病发作后出现这样的心律失常,有增加死亡的危险。试验的药物包括哌氟酰胺、哌茴苯胺和 moricizine。经过对资料的分析,接受哌氟酰胺或哌茴苯胺平
[Journal of the American Medical Association June 1989] The FDA and pharmacies that produce flecainide and encainide have notified physicians that the two drugs should only be used in life-threatening Dangerous arrhythmia patients, such as persistent ventricular tachycardia. According to the results of the Cardiac Arrhythmia Suppression Trial (CAST), these two drugs should not be considered for less severe ventricular arrhythmias even if the patient is symptomatic. The CAST study was designed to induce premature ventricular premature beats in patients with a recent heart attack and to test whether the drug can counteract their arrhythmias and thereby reduce their mortality. Because such arrhythmias occur after a heart attack, there is an increased risk of death. The drugs tested include pipeflufen, piperydine and moricizine. After analysis of the data, receive either pipefenamide or pipeifenil